Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9227782 | 0.87 | TLR2 (0.53) | TLR2ERN1TLR1TLR6NFE2L2 | |
| SCHEMBL8777227 | 0.86 | PDE3B (0.49) | SRCPDE3BPDE3ACA1CA2 | |
| SCHEMBL9176154 | 0.80 | ERN1 (0.54) | TLR2ERN1TLR1TLR6NFE2L2 | |
| SCHEMBL27990055 | 0.79 | PDE3B (0.44) | SRCPDE3BPDE3ACA1CA2 | |
| SCHEMBL5882542 | 0.78 | PDE3B (0.44) | ERN1PDE3BPDE3ALMNAALDH1A1 | |
| SCHEMBL983185 | 0.77 | TLR2 (0.51) | TLR2ERN1TLR1TLR6SRC | |
| SCHEMBL1494208 | 0.76 | ERN1 (0.58) | TLR2ERN1TLR1TLR6NFE2L2 | |
| SCHEMBL14222446 | 0.76 | TLR2 (0.50) | TLR2ERN1TLR1TLR6NFE2L2 | |
| SCHEMBL6517024 | 0.75 | TSHR (0.46) | SRCCA1CA2EGFRKDM4E | |
| SCHEMBL8413242 | 0.74 | HDAC8 (0.46) | PDE3BPDE3AKDM4EHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6001877-A | OF GIVEN FORMULA, WHICH ACTS AS AN ANTAGONIST OF LEUKOTRIENES; ADMINISTERING TO TREAT LEUKOTRIENE-B4 INDUCED DISEASES, SUCH AS ALLERGIES AND INFLAMMATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5795914-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0405116-B1 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| US-5457122-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| US-5256686-A | Antiinflammatory agent, antiallergens | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5155104-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5086065-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0405116-A2 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |